State Street Corp Has $20.26 Million Holdings in Cytokinetics, Incorporated (CYTK)

State Street Corp raised its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 79.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,674,335 shares of the biopharmaceutical company’s stock after buying an additional 741,909 shares during the quarter. State Street Corp owned about 3.12% of Cytokinetics, worth $20,259,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in Cytokinetics, by 59.9% during the 2nd quarter. Vanguard Group Inc. now owns 3,117,496 shares of the biopharmaceutical company’s stock valued at $37,721,000 after buying an additional 1,168,151 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in Cytokinetics, during the 2nd quarter valued at $32,488,000. Citigroup Inc. grew its holdings in Cytokinetics, by 9.9% during the 2nd quarter. Citigroup Inc. now owns 800,471 shares of the biopharmaceutical company’s stock valued at $9,686,000 after buying an additional 71,811 shares during the last quarter. Acadian Asset Management LLC grew its holdings in Cytokinetics, by 128.9% during the 2nd quarter. Acadian Asset Management LLC now owns 766,263 shares of the biopharmaceutical company’s stock valued at $9,271,000 after buying an additional 431,457 shares during the last quarter. Finally, Balyasny Asset Management LLC grew its holdings in Cytokinetics, by 24.5% during the 2nd quarter. Balyasny Asset Management LLC now owns 631,800 shares of the biopharmaceutical company’s stock valued at $7,645,000 after buying an additional 124,300 shares during the last quarter. Hedge funds and other institutional investors own 71.01% of the company’s stock.

In related news, CEO Robert I. Blum sold 5,000 shares of the stock in a transaction on Friday, September 1st. The stock was sold at an average price of $14.71, for a total value of $73,550.00. Following the transaction, the chief executive officer now directly owns 79,785 shares of the company’s stock, valued at approximately $1,173,637.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Caryn Gordon Mcdowell sold 4,260 shares of the stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $12.94, for a total value of $55,124.40. Following the completion of the transaction, the insider now directly owns 17,982 shares in the company, valued at $232,687.08. The disclosure for this sale can be found here. Insiders sold a total of 178,223 shares of company stock worth $2,639,239 over the last ninety days. Corporate insiders own 7.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://ledgergazette.com/2017/11/18/state-street-corp-has-20-26-million-holdings-in-cytokinetics-incorporated-cytk.html.

Cytokinetics, Incorporated (NASDAQ:CYTK) opened at $11.80 on Friday. The company has a current ratio of 7.60, a quick ratio of 7.60 and a debt-to-equity ratio of 0.14. Cytokinetics, Incorporated has a 52-week low of $9.80 and a 52-week high of $17.20.

Cytokinetics, (NASDAQ:CYTK) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.04. The business had revenue of $6.18 million for the quarter, compared to analyst estimates of $5.35 million. Cytokinetics, had a negative return on equity of 62.64% and a negative net margin of 172.27%. equities research analysts predict that Cytokinetics, Incorporated will post -2.4 EPS for the current year.

A number of equities research analysts have commented on CYTK shares. HC Wainwright reiterated a “buy” rating and set a $26.00 target price on shares of Cytokinetics, in a report on Friday, October 27th. ValuEngine raised Cytokinetics, from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Seaport Global Securities reissued a “buy” rating and set a $24.00 price target on shares of Cytokinetics, in a research note on Friday, October 6th. Morgan Stanley reissued an “overweight” rating and set a $25.00 price target (up previously from $24.00) on shares of Cytokinetics, in a research note on Friday, October 6th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $21.00 price target on shares of Cytokinetics, in a research note on Monday, September 18th. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $21.60.

About Cytokinetics,

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Want to see what other hedge funds are holding CYTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytokinetics, Incorporated (NASDAQ:CYTK).

Institutional Ownership by Quarter for Cytokinetics, (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply